Nektar Phase 2b rezpegaldesleukin meets primary endpoint; EASI-75 66% vs 34% placebo at week 16

NEKTAR THERAPEUTICS

• All three rezpegaldesleukin dose arms met primary endpoint of mean % EASI improvement at week 16 (p<0.001 vs placebo).
• High dose (24 µg/kg q2w) achieved statistical significance on EASI-75 (66% vs 34%), vIGA-AD 0/1 (19% vs 8%), and Itch NRS (42% vs 16%) at week 16.
• Placebo crossover to high dose showed deepening response: EASI-75 62% and vIGA-AD 0/1 38% at week 24.
• Safety consistent with prior data; most common AE mild injection site reactions; one death in escape arm assessed unrelated.
• Next milestones: maintenance data Q1 2026; alopecia areata data Dec 2025; Phase 3 planning underway.